Comparative Cytotoxic and Anti-Migratory Effects of Cisplatin and Theobromine in Human Bladder Cancer Cells
- 2 June 2026
- journal article
- Published by Archives of Current Medical Research in Archives of Current Medical Research
- Vol. 7 (2) , 418-425
Abstract
Background: Bladder cancer continues to pose a major global health challenge, as therapeutic options are often con-strained by treatment-related toxicity and the emergence of resistance to chemotherapy. We investigated the cytotoxic and anti-migratory effects of Theobromine, a natural alkaloid, in HT-1376 bladder cancer cells and compared its activity with Cisplatin, a standard chemotherapeutic agent.Methods: Cellular metabolic activity was quantified via the WST-1 colorimetric assay, while migratory capacity was examined using wound healing assay.Results: Treatment with Theobromine induced a time- and dose-responsive decrease in HT-1376 cell viability, with IC₅₀ values of 134.3 µM after 24 h, while Cisplatin exhibited stronger cytotoxicity with an IC₅₀ value of 35.97 µM. Both agents significantly inhibited cell migration, with the combination of Theobromine and Cisplatin showing the most pronounced anti-migratory effect. The wound healing assay revealed that the combination treatment significantly reduced wound closure compared to either compound alone (p < 0.0001), while Theobromine alone resulted in moderate inhibition (p = 0.0001). Importantly, no significant cytotoxicity was observed in NIH/3T3 fibroblast cells at concentrations up to 200 µM for Theobromine and 50 µM for Cisplatin, indicating differential sensitivity between bladder cancer cells and normal fibroblast cells.Conclusion: These findings suggest that Theobromine may act as a potential adjunct to Cisplatin-based therapy in blad-der cancer cells. Further experimental studies are required to elucidate the underlying molecular mechanisms responsible for the enhanced inhibitory effect and to evaluate the efficacy of this combined treatment in animal models.Keywords
Funding Information
- No funding was received for this study.
This publication has 22 references indexed in Scilit:
- Theobromine as a molecular switch: targeting Nrf2 pathway in invasive and non-invasive bladder cancerJournal of Natural Medicines, 2025
- β-Arbutin and cisplatin: A combined approach to modulating apoptosis, cell viability, and migration in bladder cancer cellsToxicology in Vitro, 2024
- Health benefits and mechanisms of theobromineJournal of Functional Foods, 2024
- Global trends in the epidemiology of bladder cancer: challenges for public health and clinical practiceNature Reviews Clinical Oncology, 2023
- Cisplatin for cancer therapy and overcoming chemoresistanceHeliyon, 2022
- Natural products targeting into cancer hallmarks: An update on caffeine, theobromine, and (+)-catechinCritical Reviews in Food Science and Nutrition, 2021
- Management of cisplatin-associated toxicities in bladder cancer patientsCurrent Opinion in Supportive & Palliative Care, 2020
- Cisplatin enhances cell stiffness and decreases invasiveness rate in prostate cancer cells by actin accumulationScientific Reports, 2019
- Mechanisms of Metastasis2013
- Cisplatin: mode of cytotoxic action and molecular basis of resistanceOncogene, 2003